Treatment-limiting motor complications occur in patients with
Parkinson's disease after chronic
levodopa (
L-DOPA) treatment, and represent an unmet medical need. We examined the motor and neurochemical effects of the dopaminergic stabilizer
pridopidine (NeuroSearch A/S, Ballerup, Denmark) in the unilateral rodent
6-OHDA lesion model, which is often used to evaluate the potential of experimental compounds for such
dopamine-related motor complications. In total, 72 rats were hemi-lesioned and allocated to receive twice-daily
injections of either vehicle; 6.5mg/kg
L-DOPA;
L-DOPA + 25 μmol/kg
pridopidine; or
L-DOPA + 25 μmol/kg (-)-OSU6162-a prototype dopaminergic stabilizer used previously in
6-OHDA hemi-lesion models. Animals were treated for 7, 14 or 21 days, and locomotor activity and ex vivo brain tissue neurochemistry analysed. In agreement with previous studies,
L-DOPA sensitised the motor response, producing significantly more contralateral rotations than vehicle (P<0.05). Concomitant administration of
pridopidine and
L-DOPA significantly decreased the number of
L-DOPA-induced contralateral rotations on day 7, 14 and 21 (P<0.05 versus
L-DOPA alone), while still allowing a beneficial locomotor stimulant effect of
L-DOPA. Concomitant
pridopidine also reduced
L-DOPA-induced rotation asymmetry (P<0.05 versus
L-DOPA alone) and had no adverse effects on distance travelled. Brain neurochemistry was generally unaffected in all treatments groups. In conclusion,
pridopidine shows potential for reducing motor complications of
L-DOPA in
Parkinson's disease and further testing is warranted.